Effect of an intervention to increase statin use in medicare members who qualified for a medication therapy management program

Journal of Managed Care Pharmacy

Volumn 14, Issue 6, 2008, Pages 532-540

  Stockl, Karen M ^a   Tjioe, Daniel ^a   Gong, Sherry ^a   Stroup, Jenni ^a   Harada, Ann S M ^a   Lew, Heidi C ^a  

^a Prescription Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL PRACTICE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; DIABETES MELLITUS; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; GEOGRAPHY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH PROGRAM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; OUTCOME ASSESSMENT; PATIENT EDUCATION; PHARMACY BENEFIT MANAGER; PRESCRIPTION; RISK REDUCTION; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES;

EID: 51349143606     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.6.532     Document Type: Article

References (24)

1. Grundy S, Cleeman J, Merz N, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-39.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-57.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934): 1383-89.
4. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-07.
5. Johannesson M, Jonsson B, Kjekshus J, et al. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997;336(5)332-36.
6. Shepherd J, Blauw GJ, Murphy ME, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-30.
7. Lewis S, Moye L, Sacks F, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129(9):681-89.
8. Lewis S, Sacks F, Mitchell J, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998;32(1):140-46.
9. Costa J, Borges M, Claudio D, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;332:1115-24.
10. Ashraf T, Hay J, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996;78(4):409-14.
11. Elliott WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm. 1999,56(17):1726-32.
12. Debusk R, Miller N, Superko H, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120(9):721-29.
13. Fonarow G, French W, Parsons L, Sun H, Malmgren J. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001 103(1):38-44.
14. Majumdar S, Gurwitz J, Soumerai S. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1999;14(12):711-17.
15. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285(4):430-36.
16. Sueta C, Chowdhury M, Boccuzzi S, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83(9):1303-07.
17. Lee H, Cooke C, Robertson T. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm. 2008;14(3):271-80. Available at: www.amcp.org/data/ jmcp/JMCPMaga_April08_271-280.pdf.
18. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31(suppl 1):S12-S54.
19. Lester W, Grant R, Octo B, Chueh H. Randomized controlled trial of an informatics-based intervention to increase statin prescription for secondary prevention of coronary disease. J Gen Intern Med. 2006;21:22-29.
20. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197-203.
21. Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm. 2005;11(4): 300-06. Available at: www.amcp.org/data/jmcp/ research_300_306.pdf.
22. U.S. Dept. of Labor. Bureau of Labor Statistics. Consumer Price Index. Washington, DC: U.S. Dept. of Labor. Available at: www.bls.gov. Accessed June 17, 2008.
23. Chan V, Cooke CE. Pharmacotherapy after myocardial infarction: disease management versus usual care. Am J Manag Care. 2008;14(6):352-58.
24. Centers for Medicare & Medicaid Services. Medication Therapy Management. Available at: www.cms.hhs.gov/PrescriptionDrugCovContra/ 082_MTM.asp#TopOfPage. Accessed June 18, 2008.